Eli Lilly Sues Six Firms Over Black-Market Sales of Experimental Obesity Drug Retatrutide
Key Takeaways
- •Eli Lilly named six defendants in lawsuits alleging illegal sales of black-market retatrutide products.
- •Retatrutide is still in Phase 3 clinical trials and has not been approved by any regulator for human use.
- •The FDA said in June that retatrutide and other unapproved GLP-1 products cannot be legally sold or compounded.
- •Lilly has referred more than 200 people and entities to regulators and law enforcement agencies.
- •U.S. Customs and Border Protection reported more than 690 shipments of illicit GLP-1 drugs in fiscal 2025, with seizures rising sharply in July.
Eli Lilly (LLY) has filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental weight-loss drug retatrutide. Shares of LLY were trading down 0.68% on Wednesday.
The lawsuits name Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide as defendants. These entities span compounding pharmacies, medical spas, and online resellers.
Retatrutide is currently in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions. No regulator has approved the drug for human use. In June, the FDA stated clearly that sales of retatrutide and other unapproved GLP-1 products are illegal and cannot lawfully be compounded. Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon pathways, a mechanism that distinguishes it from Lilly's approved incretin therapies Mounjaro and Zepbright and from Novo Nordisk's Ozempic and Wegovy. Phase 2 trial data showed mean weight reductions approaching 24%, contributing to high anticipation for the drug and helping explain the demand that black-market sellers have sought to exploit.
"What is being sold on the black market is not a medicine. It is entirely unverified, unapproved and not worth the risk," said Lilly Chief Medical Officer Dr. David Hyman.
Despite the regulatory stance, strong demand for obesity treatments has fueled a thriving online market. Some sellers have promoted retatrutide through websites, social media platforms, and businesses presenting themselves as legitimate medical providers. Lilly says these sellers source products from unregulated manufacturers, raising serious patient safety concerns.
Lilly Escalates Enforcement Push
Beyond the six lawsuits, Lilly has referred more than 200 individuals and entities to the FDA, the U.S. Justice Department, state attorneys general, and other law enforcement agencies.
The company is also urging social media platforms, e-commerce sites, payment processors, credit card companies, and shipping firms to take stronger action against sellers of unapproved retatrutide products.
"Every single time that someone takes one of these, they're exposing themselves to a huge amount of risk," said Dr. Max Denning, Lilly's Associate Vice President and Therapeutic Area Lead for Global Patient Safety, Cardiometabolic Health.
Seizures Surging at the Border
The scale of the illicit trade is expanding rapidly. U.S. Customs and Border Protection intercepted over 690 shipments, totaling more than 31,000 units, of illicit GLP-1 drugs during fiscal year 2025.
In July alone, those figures more than doubled. Customs agents recorded over 1,400 seizures and intercepted nearly 90,000 vials in a single month.
The surge underscores how quickly the black market for unapproved GLP-1 drugs has grown, driven by consumer demand for weight-loss treatments that has outpaced the legitimate supply of approved therapies.
Lilly's campaign against unauthorized retatrutide sellers began before the current round of lawsuits. Wednesday's filings represent the company's most direct legal action yet against named defendants.
